id:"swepub:oai:DiVA.org:kth-289401"
Search: id:"swepub:oai:DiVA.org:kth-289401" > Small Bispecific Af...
- 1 of 1
- Previous record
- Next record
- To hitlist
Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension
-
- von Witting, Emma (author)
- KTH,Proteinvetenskap
-
- Lindbo, Sarah (author)
- KTH,Proteinvetenskap
-
- Lundqvist, Magnus (author)
- KTH,Proteinvetenskap
- show more...
- show less...
- (creator_code:org_t)
- 2020-12-01
- 2021
- English.
- In: Molecular Pharmaceutics. - : American Chemical Society (ACS). - 1543-8384 .- 1543-8392. ; 18:1, s. 328-337
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Albumin-binding fusion partners are frequently used as a means for the in vivo half-life extension of small therapeutic molecules that would normally be cleared very rapidly from circulation. However, in applications where small size is key, fusion to an additional molecule can be disadvantageous. Albumin-derived affinity proteins (ADAPTs) are a new type of scaffold proteins based on one of the albumin-binding domains of streptococcal protein G, with engineered binding specificities against numerous targets. Here, we engineered this scaffold further and showed that this domain, as small as 6 kDa, can harbor two distinct binding surfaces and utilize them to interact with two targets simultaneously. These novel ADAPTs were developed to possess affinity toward both serum albumin as well as another clinically relevant target, thus circumventing the need for an albumin-binding fusion partner. To accomplish this, we designed a phage display library and used it to successfully select for single-domain bispecific binders toward a panel of targets: TNFα, prostate-specific antigen (PSA), C-reactive protein (CRP), renin, angiogenin, myeloid-derived growth factor (MYDGF), and insulin. Apart from successfully identifying bispecific binders for all targets, we also demonstrated the formation of the ternary complex consisting of the ADAPT together with albumin and each of the five targets, TNFα, PSA, angiogenin, MYDGF, and insulin. This simultaneous binding of albumin and other targets presents an opportunity to combine the advantages of small molecules with those of larger ones allowing for lower cost of goods and noninvasive administration routes while still maintaining a sufficient in vivo half-life.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology (hsv//eng)
Keyword
- Bioteknologi
- Biotechnology
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Molecular Pharmaceutics (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- von Witting, Emm ...
- Lindbo, Sarah
- Lundqvist, Magnu ...
- Möller, Marit
- Wisniewski, Andr ...
- Kanje, Sara, 198 ...
- show more...
- Rockberg, Johan
- Tegel, Hanna
- Åstrand, Mikael
- Uhlén, Mathias
- Hober, Sophia
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Medical Biotechn ...
- Articles in the publication
- Molecular Pharma ...
- By the university
- Royal Institute of Technology
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
